| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Institute of Toxicology, Chung Shan Medical College, Taichung, Taiwan 40203, Republic of China [Y-C. W., S-K. C., Y-Y. C., P. L.], and Department of Thoracic Surgery, Veteran General Hospital-Taichung, Taiwan 40705, Republic of China [C-Y. C.]
An association between the BstUI (Pro/Pro) genotype of the p53 codon 72 polymorphism and lung cancer has been reported previously (X. Jin et al., Carcinogenesis (Lond.), 16: 2205–2208, 1995). However, the genotype distribution of p53 codon 72 polymorphism as well as the association of this polymorphism with lung cancer risk and prognosis remain undefined in the Taiwanese population. Therefore, we investigated the genotype distribution of p53 codon 72 polymorphism in 194 lung cancer patients and 152 noncancer controls. The genotype frequencies in Taiwanese noncancer controls were 0.56 (Arg) and 0.44 (Pro). 
2 analysis indicated significant differences in genotype distribution of p53 from other reports in Swedish (P < 0.001), Spanish (P < 0.001), Caucasians in the United States (P = 0.002), and African-Americans (P = 0.027). In addition, our data suggest that the Pro allele of the p53 codon 72 polymorphism increased the risk of lung cancer among female Taiwanese. The female patients with genotype Pro/Pro showed a significantly increased odds ratio (3.14; confidence interval, 1.48–6.64; P = 0.003) of having lung adenocarcinoma, compared with normal controls with the other genotypes. Patients with the Pro/Pro genotype had an odds ratio of 2.63 (confidence interval, 1.22–5.68; P = 0.01) higher than those with the other genotypes to be diagnosed with lung cancer at the early ages. We further investigated the association of p53 codon 72 polymorphism with prognosis in 133 lung cancer patients. Patients with the Pro/Pro genotype tended to have poorer prognosis than those with the Arg/Pro genotype (P = 0.05, by the log-rank test). Our data suggested that p53 codon 72 polymorphism may play a role in cancer susceptibility and prognosis in specific classes of lung cancer patients in Taiwan.
This article has been cited by other articles:
|
|
 |
|
  K. Arizono, Y. Osada, and Y. Kuroda DNA Repair Gene hOGG1 Codon 326 and XRCC1 Codon 399 Polymorphisms and Bladder Cancer Risk in a Japanese Population Jpn. J. Clin. Oncol., March 1, 2008; 38(3): 186 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-P. Huang, C.-Y. Huang, J.-S. Wang, C.-C. Liu, Y.-S. Pu, H.-J. Yu, C.-C. Yu, T. T. Wu, C.-H. Huang, W.-J. Wu, et al. Prognostic Significance of p53 and X-ray Repair Cross-complementing Group 1 Polymorphisms on Prostate-Specific Antigen Recurrence in Prostate Cancer Post Radical Prostatectomy Clin. Cancer Res., November 15, 2007; 13(22): 6632 - 6638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Matakidou, R. el Galta, E. L. Webb, M. F. Rudd, H. Bridle, the GELCAPS Consortium, T. Eisen, and R. S. Houlston Genetic variation in the DNA repair genes is predictive of outcome in lung cancer Hum. Mol. Genet., October 1, 2007; 16(19): 2333 - 2340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wrensch, A. McMillan, J. Wiencke, J. Wiemels, K. Kelsey, J. Patoka, H. Jones, V. Carlton, R. Miike, J. Sison, et al. Nonsynonymous Coding Single-Nucleotide Polymorphisms Spanning the Genome in Relation to Glioblastoma Survival and Age at Diagnosis Clin. Cancer Res., January 1, 2007; 13(1): 197 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Tommiska, H. Eerola, M. Heinonen, L. Salonen, M. Kaare, J. Tallila, A. Ristimaki, K. von Smitten, K. Aittomaki, P. Heikkila, et al. Breast Cancer Patients with p53 Pro72 Homozygous Genotype Have a Poorer Survival Clin. Cancer Res., July 15, 2005; 11(14): 5098 - 5103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hu, M. P. McDermott, and S. A. Ahrendt The p53 Codon 72 Proline Allele Is Associated with p53 Gene Mutations in Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2005; 11(7): 2502 - 2509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-P. Huang, W.-J. Wu, W.-S. W. Chang, M.-T. Wu, Y.-Y. Chen, Y.-J. Chen, C.-C. Yu, T. T. Wu, Y.-H. Lee, J.-K. Huang, et al. p53 Codon 72 and p21 Codon 31 Polymorphisms in Prostate Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2217 - 2224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-W. Zhang, N. J. Laurence, A. Hollowood, P. Newcomb, M. Moorghen, J. Gupta, R. Feakins, M. J. G. Farthing, D. Alderson, and J. Holly Prognostic Value of TP53 Codon 72 Polymorphism in Advanced Gastric Adenocarcinoma Clin. Cancer Res., January 1, 2004; 10(1): 131 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Matakidou, T. Eisen, and R.S. Houlston TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis Mutagenesis, July 1, 2003; 18(4): 377 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-W. Zhang, P. Newcomb, A. Hollowood, R. Feakins, M. Moorghen, A. Storey, M. J. G. Farthing, D. Alderson, and J. Holly Age-associated Increase of Codon 72 Arginine p53 Frequency in Gastric Cardia and Non-Cardia Adenocarcinoma Clin. Cancer Res., June 1, 2003; 9(6): 2151 - 2156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H-J Lin, W-C Chen, F-J Tsai, and S-W Tsai Distributions of p53 codon 72 polymorphism in primary open angle glaucoma Br. J. Ophthalmol., July 1, 2002; 86(7): 767 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wu, H. Zhao, C. I. Amos, S. Shete, N. Makan, W. K. Hong, F. F. Kadlubar, and M. R. Spitz p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity J Natl Cancer Inst, May 1, 2002; 94(9): 681 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Furihata, T. Takeuchi, M. Matsumoto, A. Kurabayashi, Y. Ohtsuki, N. Terao, M. Kuwahara, and T. Shuin p53 Mutation Arising in Arg72 Allele in the Tumorigenesis and Development of Carcinoma of the Urinary Tract Clin. Cancer Res., May 1, 2002; 8(5): 1192 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Pierce, L. Sivaraman, W. Chang, A. Lum, T. Donlon, A. Seifried, L. R. Wilkens, A. F. Lau, and L. Le Marchand Relationships of TP53 Codon 72 and HRAS1 Polymorphisms with Lung Cancer Risk in an Ethnically Diverse Population Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1199 - 1204. [Abstract] [Full Text]
|
|
|
|
|
|
R. Fan, M.-T. Wu, D. Miller, J. C. Wain, K. T. Kelsey, J. K. Wiencke, and D. C. Christiani The p53 Codon 72 Polymorphism and Lung Cancer Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2000; 9(10): 1037 - 1042. [Abstract] [Full Text]
|
|
|
|
|
|
P. Berggren, K. Hemminki, and G. Steineck p53 intron 7 polymorphisms in urinary bladder cancer patients and controls Mutagenesis, January 1, 2000; 15(1): 57 - 60. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
